Basilea Pharmaceutica (OTCMKTS:BPMUF) Raised to Strong-Buy at HC Wainwright

HC Wainwright upgraded shares of Basilea Pharmaceutica (OTCMKTS:BPMUF) to a strong-buy rating in a report released on Monday, Zacks.com reports.

Basilea Pharmaceutica Stock Performance

Shares of OTCMKTS:BPMUF opened at $51.26 on Monday. The business has a fifty day moving average price of $49.39 and a 200-day moving average price of $46.67. Basilea Pharmaceutica has a 1-year low of $38.60 and a 1-year high of $51.26.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.